6-hydroxy-2-methoxyquinoline | 623147-03-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-hydroxy-2-methoxyquinoline
• 英文别名: 2-methoxy-6-quinolinol；2-methoxyquinolin-6-ol
• CAS: 623147-03-5
• 化学式: C₁₀H₉NO₂
• 分子量: 175.187
• InChiKey: HNLXDDVEGXVWFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  42.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-hydroxy-2-methoxyquinoline 、 1,8-二溴辛烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 1.0h， 生成 6-(8-bromooctyloxy)-2-methoxyquinoline
  参考文献：
  名称：

  [EN] NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION
  [FR] COMPOSÉ CONTENANT DE L'AZOTE ET COMPOSITION PHARMACEUTIQUE

  摘要：

  公开号：

  WO2011021726A3

文献信息

• [EN] 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS<br/>[FR] DERIVES DE 2,6-QUINOLINYLE ET DE 2,6-NAPHTYLE, LEURS PROCEDES DE PREPARATION ET LEUR UTILISATION COMME INHIBITEURS DE VLA-4
  申请人：UCB SA

  公开号：WO2003093237A1

  公开（公告）日：2003-11-13

  The present invention concerns 2,6-quinolinyl and 2,6-naphthyl derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for the treatment of VLA-4 dependent inflammatory diseases such as for example asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and atherosclerosis. Formula (I): wherein X is N or CH.

  本发明涉及式(I)的2,6-喹啉基和2,6-萘基衍生物，制备它们的方法，含有它们的药物组合物以及它们作为治疗VLA-4依赖性炎症性疾病的药物的用途，例如哮喘、过敏性鼻炎、鼻窦炎、结膜炎、食物过敏、牛皮癣、荨麻疹、瘙痒、湿疹、类风湿关节炎、炎症性肠病、多发性硬化和动脉粥样硬化等。式(I)：其中X为N或CH。
• 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors
  申请人：Lassoie Marie-Agnes

  公开号：US20080064720A1

  公开（公告）日：2008-03-13

  The present invention concerns 2,6-quinolinyl and 2,6-naphthyl derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for the treatment of VLA-4 dependent inflammatory diseases such as for example asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and atherosclerosis. Formula (I): wherein X is N or CH.

  本发明涉及公式(I)的2,6-喹啉基和2,6-萘基衍生物，其制备方法，含有它们的制药组合物以及它们作为药物治疗VLA-4依赖性炎症性疾病的用途，例如哮喘、过敏性鼻炎、鼻窦炎、结膜炎、食物过敏、银屑病、荨麻疹、瘙痒、湿疹、类风湿性关节炎、炎症性肠病、多发性硬化和动脉粥样硬化。公式(I)中，X为N或CH。
• 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS
  申请人：Lassoie Marie-Agnes

  公开号：US20100105681A1

  公开（公告）日：2010-04-29

  The present invention concerns 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

  本发明涉及2,6-喹啉基和2,6-萘基衍生物，其制备工艺，含有它们的制药组合物以及它们作为药物的用途。
• NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION
  申请人：Oshima Kunio

  公开号：US20120225866A1

  公开（公告）日：2012-09-06

  The present invention provides a novel diazepine compound that blocks the I Kur current or the Kv1.5 channel potently and more selectively than other K + channels. The present invention relates to a diazepine compound represented by General Formula (1) or a salt thereof, wherein R 1 , R 2 , R 3 , and R 4 are each independently hydrogen, lower alkyl, cyclo lower alkyl or lower alkoxy lower alkyl; R 2 and R 3 may be linked to form lower alkylene; A 1 is lower alkylene optionally substituted with one or more substituents selected from the group consisting of hydroxyl and oxo; Y 1 and Y 2 are each independently —N═ or —CH═; and R 5 is group represented by wherein R 6 and R 7 are each independently hydrogen or organic group; R 6 and R 7 may be linked to form a ring together with the neighboring group —X A —N—X B —; X A and X B are each independently a bond, lower alkylene, etc.

  本发明提供了一种新型的二氮杂环化合物，它可以有效地阻断IKur电流或Kv1.5通道，并比其他K+通道更具选择性。本发明涉及一种由通式（1）表示的二氮杂环化合物或其盐，其中R1、R2、R3和R4各自独立地表示氢、低碳基、环状低碳基或低烷氧基低碳基；R2和R3可以连接形成低碳烷基；A1是低碳烷基，可选地取代一个或多个羟基和氧代基；Y1和Y2各自独立地表示—N═或—CH═；R5是由下式表示的基：其中R6和R7各自独立地表示氢或有机基团；R6和R7可以与相邻的基团—XA—N—XB—一起形成环；XA和XB各自独立地表示键、低碳烷基等。
• Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation
  申请人：Matsumura Shuuji

  公开号：US08822453B2

  公开（公告）日：2014-09-02

  The present invention provides a novel diazepine compound that blocks the IKur current or the Kv1.5 channel potently and more selectively than other K+ channels. The present invention relates to a diazepine compound represented by General Formula (1) or a salt thereof, wherein R1, R2, R3, and R4 are each independently hydrogen, lower alkyl, cyclo lower alkyl or lower alkoxy lower alkyl; R2 and R3 may be linked to form lower alkylene; A1 is lower alkylene optionally substituted with one or more substituents selected from the group consisting of hydroxyl and oxo; Y1 and Y2 are each independently —N═ or —CH═; and R5 is group represented by wherein R6 and R7 are each independently hydrogen or organic group; R6 and R7 may be linked to form a ring together with the neighboring group —XA—N—XB—; XA and XB are each independently a bond, lower alkylene, etc.

  本发明提供了一种新型二氮杂烷化合物，可比其他K+通道更有效地和更选择性地阻断IKur电流或Kv1.5通道。本发明涉及一种由通式（1）表示的二氮杂烷化合物或其盐，其中R1、R2、R3和R4各自独立地为氢、低碳基、环低碳基或低烷氧基低碳基；R2和R3可以连接形成低碳烷基；A1是低碳烷基，可选地取代一个或多个取代基，所述取代基选择自羟基和氧代基；Y1和Y2各自独立地为—N═或—CH═；以及R5是由以下式子表示的基：其中R6和R7各自独立地为氢或有机基团；R6和R7可以与相邻的基团—XA—N—XB—一起形成环；XA和XB各自独立地为键、低碳烷基等。